Skip to main content
. Author manuscript; available in PMC: 2022 May 20.
Published in final edited form as: Sci Transl Med. 2021 Mar 24;13(586):eabd6737. doi: 10.1126/scitranslmed.abd6737

Fig. 5. Inhibition of the hepatic Ashwell-Morell receptor (AMR) supports platelet-mediated defense against SA bacteremia.

Fig. 5.

(A) C57/Bl6 (n = 4) and Asgr2−/− (n = 6) mice were challenged by intraperitoneal injection with SA, blood harvested by cardiac puncture, and platelet count enumerated. (B) 10-day mortality study with C57/Bl6 (n = 22) and Asgr2−/− mice (n = 16) challenged by intraperitoneal injection with SA. Study performed two independent times and data pooled. (C) 8-day mortality study with C57/Bl6 treated with fetuin (n = 10) or asialofetuin (n = 10) and challenged by intraperitoneal injection with SA. (D) C57/Bl6 mice treated with asialofetuin (n = 4) or fetuin (n = 4) and challenged by intraperitoneal injection with SA, platelet count enumerated, and (E) kidneys, liver, spleen, and blood harvested 24 h post-infection for bacterial CFU enumeration. (F) C57/Bl6 and Asgr2−/− mice challenged with wild-type MRSA or the isogenic ΔHla mutant. 4 h post-infection, blood was harvested by cardiac puncture for enumeration of platelet count. Statistical significance was determined by unpaired two-tailed Student’s t-test (E), two-way ANOVA with Bonferroni’s multiple comparisons posttest (A,D,F) or log-rank (Mantel-Cox) Test (B,C) for the survival curves. For floating bar graphs, + denotes the mean, whiskers represent min. to max, and floating box represents 25th to 75th percentile. *P < 0.05, **P < 0.005. PBS, phosphate buffered saline; ns, not significant.